

## AMENDMENTS

### *In the claims:*

1. (Original) A method for modulating tumor growth or metastasis in an animal in need thereof, comprising sequential or simultaneous administration of at least one anticancer agent, and a combretastatin A-4 compound in amounts effective therefor.
2. (Original) A method for modulating tumor growth or metastasis in an animal in need thereof, comprising administration of a combretastatin A-4 compound and at least one anticancer agent, in amounts effective therefor, wherein said combretastatin A-4 compound is administered at a time relative to administration of said anticancer agent sufficient to modulate blood flow to said tumor to provide a time-dependent effective tumor concentration of said anticancer agent.
3. (Currently Amended) The method as claimed in claim 1, wherein said at least one anti-cancer agent is ~~selected from the group consisting of alkylating agents, bifunctional alkylating agents, non-steroidal aromatase inhibitors, immunotherapeutic agents, nitrosurea compounds, antimetabolites, antitumor antibiotics, a mitotic inhibitors, radiation, topoisomerase I inhibitors, and anti-estrogens.~~
4. (Currently Amended) The method as claimed in claim 1, wherein said at least one anticancer agent is selected from the group consisting of ~~cisplatin, carboplatin, oxaliplatin, radiation, CPT-11, paclitaxel, 5-fluorouracil, leucovorin, epothilone, gemcitabine, UFT, herceptin, cytoxan, dacarbazine, ifosfamide, mechlorethamine, melphalan, chlorambucil, anastrozole and exemstane, carmustine, lomustine, methotrexate, gemcitabine, cytarabine, fludarabine, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, and docetaxel, vinblastine, vincristin, vinorelbine, topotecan, lupron, megace, leucovorin, Iressa, flavopiridol, immunomotherapeutic agents, ZD6474, SU6668, and valspodar.~~
- 5.-6. (Cancelled)

7. (Currently Amended) The method as claimed in claim 21 wherein said anticancer agent is a duration exposure agent and is administered ~~after the administration of the~~ sequentially in any order with said combretastatin A4 compound.

8. (Currently Amended) The method as claimed in claim 7, wherein said duration exposure agent is ~~selected from the group consisting of a taxanes, etoposide, etoposide phosphate, immunotoxins and epothilones.~~

9.-13. (Cancelled)

14. (Currently Amended) The method as claimed in claim 8, wherein said combretastatin A4 compound is a combretastatin A-4 phosphate prodrug disodium salt and said taxane is paclitaxel.

15. (Currently Amended) The method as claimed in claim 14, wherein said combretastatin A4 phosphate prodrug disodium salt is administered at least 3 hours prior to paclitaxel.

16.-21. (Cancelled)

22. (Original) A pharmaceutical composition for modulating tumor growth or metastasis in an animal in need thereof, comprising at least one anticancer agent, and a combretastatin A-4 compound, in amounts effective therefore in a pharmaceutically acceptable carrier.

23. (Currently Amended) The pharmaceutical composition as claimed in claim 22, wherein said at least one anticancer agent is ~~selected from the group consisting of a taxane~~ selected from the group consisting of a taxane cisplatin, carboplatin, oxaliplatin, radiation, CPT-11, paclitaxel, 5-fluorouracil, leucovorin, epothilone, gemcitabine, UFT, hereceptin, cytoxan, dacarbazine, ifosfamide, mechlorethamine, melphalan, chlorambucil, anastrozole and exemstane, carmustine, lomustine, methotrexate, gemcitabine, cytarabine, mitomycin C, fludarabine, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, docetaxel, vinblastine, vincristin, vinorelbine, topotecan, lupron, megace, leucovorin, Iressa, flavopiridol, an immunotherapeutic agent, ZD6474, SU6668, and valspodar.

24. (Currently Amended) The pharmaceutical composition of claim 23, wherein said combretastatin A-4 compound is a combretastatin A-4 phosphate prodrug disodium salt.

25.-36. (Cancelled)

37. (Currently Amended) The pharmaceutical composition as claimed in claim 23, wherein said ~~anti-cancer agent~~ taxane is paclitaxel.

38. (as renumbered; formerly claim 39) (Currently Amended) The pharmaceutical composition as claimed in claim 24, wherein said ~~anti-cancer agent~~ taxane is paclitaxel.

39-59. (as renumbered; formerly claims 40-60) (Cancelled)

60. (Cancelled)

61. (New) The method of claim 14, wherein said paclitaxel is administered at least 24 hours prior to said combretastatin A4 phosphate prodrug salt.

62. (New) The method of claim 1, comprising administration of a second anticancer agent.

63. (New) The method of claim 62, wherein said anticancer agent is a taxane and said second anticancer agent is an alkylating agent.

64. (New) The method of claim 62, wherein said second anticancer agent is selected from the group consisting of: cisplatin, carboplatin, and oxaliplatin.

65. (New) The method of claim 63, wherein said taxane is paclitaxel and said alkylating agent is carboplatin.

66. (New) The method of claim 65, wherein paclitaxel and carboplatin are administered simultaneously to each other and at least 24 hours prior to said combretastatin A-4 compound.

67. (New) The pharmaceutical composition of claim 22, comprising a second anticancer agent.
68. (New) The pharmaceutical composition of claim 67, wherein said second anticancer agent is selected from the group consisting of: cisplatin, carboplatin, and oxaliplatin.
69. (New) The pharmaceutical composition of claim 68, wherein said second anticancer agent is carboplatin.
70. (New) The pharmaceutical composition of claim 37, comprising a second anticancer agent.
71. (New) The pharmaceutical composition of claim 70, wherein said second anticancer agent is selected from the group consisting of: cisplatin, carboplatin, and oxaliplatin.
72. (New) The pharmaceutical composition of claim 71, wherein said second anticancer agent is carboplatin.
73. (New) The pharmaceutical composition of claim 39, comprising a second anticancer agent.
74. (New) The pharmaceutical composition of claim 73, wherein said second anticancer agent is selected from the group consisting of: cisplatin, carboplatin, and oxaliplatin.
75. (New) The pharmaceutical composition of claim 74, wherein said second anticancer agent is carboplatin.
76. (New) The method of claim 1, wherein said tumor is a breast cancer, ovarian cancer, lung carcinoma, renal carcinoma, or bladder carcinoma.